[10] Divi's Laboratories is India's fourth largest publicly listed pharmaceutical company by market capitalization.

[11] In October 2024, Divi and his family were ranked 29th on Forbes list of India’s 100 richest tycoons, with a net worth of $9.2 billion.

[12] The company initially started developing commercial processes for the manufacturing of APIs and intermediates.

[1] Divi's Laboratories has between 60 and 85% global market share in generic naproxen, dextromethorphan and gabapentin APIs.

[15] The company currently has between 20 and 30% global market share in pregabalin and methylamine APIs.